

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | ULIXERTINIB |
| INN | ulixertinib |
| Description | Ulixertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mitogen-activated protein kinase 3 and mitogen-activated protein kinase 1. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1 |
| PDB | — |
| CAS-ID | 869886-67-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3590106 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 16ZDH50O1U (ChemIDplus, GSRS) |
